Harvard Bioscience gets Nasdaq notice over audit-committee shortfall
Rhea-AI Filing Summary
Harvard Bioscience (HBIO) filed an amended Form 8-K to restate Item 3.01 and confirm that Nasdaq has formally determined the company is out of compliance with Listing Rule 5605(c)(2)(A), which requires at least three independent directors on the audit committee. The shortfall was triggered by director Alan Edrick’s resignation on 10 Jun 2025, leaving only two audit-committee members. Nasdaq’s notice was received on 26 Jun 2025.
HBIO states it will appoint a new, fully independent director “as expeditiously as practicable” and will rely on the cure period in Rule 5605(c)(4), giving the company until the earlier of its next annual shareholders’ meeting or 10 Jun 2026 to regain compliance. Until then, the company remains subject to potential delisting if it fails to add a qualified director within the allowed timeframe. No financial statements, earnings metrics or transactional details were included in this filing.
Positive
- Cure period until 10 Jun 2026 gives the company sufficient time to recruit an independent director and avoid immediate delisting risk.
Negative
- Nasdaq non-compliance notice increases the risk of eventual delisting if an independent director is not appointed in time.
- Audit-committee vacancy signals a governance weakness that could affect investor confidence and institutional ownership thresholds.
Insights
TL;DR: Nasdaq audit-committee shortfall elevates governance risk; curable within a year but negative for investor sentiment.
This amended 8-K confirms that HBIO now has an official Nasdaq deficiency notice under Rule 5605(c)(2)(A). Losing a qualified audit-committee member is immediately material because audit oversight is central to investor confidence. While the rule grants up to one year—or the next AGM—to remedy the gap, the company has not yet named a replacement. Historically, most issuers resolve such issues well before the deadline, but failure would result in a hearing process and potential delisting. Until a new independent director is appointed, rating agencies and some institutional investors may impose governance penalties, potentially widening the firm’s cost of capital. The risk is concentrated in reputational impact rather than liquidity, yet any hint of delisting can depress share liquidity and valuation multiples in the near term.
UNITED STATES
SECURITIESAND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________
FORM
(Amendment No. 1)
_________________
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities ExchangeAct of 1934
Date of Report (Date of earliest event reported):
_______________________________
(Exact name of registrant as specified in its charter)
______________________________
| (State or Other Jurisdiction of Incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.) |
(Address of Principal Executive Offices) (Zip Code)
(Registrant's telephone number, including area code)
(Former name or former address, if changed since last report)
____________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Securities registered pursuant to Section 12(b) of theAct:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the SecuritiesAct of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities ExchangeAct of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 3.01. | Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. |
On June 18, 2025, Harvard Bioscience, Inc. (the “Company”) notified the Nasdaq Stock Market LLC (“Nasdaq”) that the Company is not in compliance with the audit committee requirement set forth in Nasdaq Listing Rule 5605(c)(2)(A) (the “Audit Committee Composition Requirement”) due to the Company having only two members on the audit committee (the “Audit Committee”) of its Board of Directors (the “Board”). The Company’s current failure to comply with the Audit Committee Composition Requirement is due to a vacancy resulting from Alan Edrick’s resignation from the Board and the Audit Committee effective June 10, 2025.
On June 26, 2025, the Company received a letter from the staff at the Listing Qualifications Department of Nasdaq (the "Staff") notifying the Company that the Staff had determined that the Company no longer complies with the Audit Committee Composition Requirement.
The Company intends to regain compliance with Nasdaq Listing Rule 5605(c)(2)(A) by appointing a new Board member who meets the independence requirements under Nasdaq rules and Rule 10A-3(b)(1) under the Securities Exchange Act of 1934, as amended, as expeditiously as practicable. Until such appointment, the Company plans to rely on the cure period set forth in Nasdaq Listing Rule 5605(c)(4), which gives the Company until the earlier of (i) the Company’s next annual meeting of stockholders or (ii) one year from Mr. Edrick’s resignation, or June 10, 2026 to satisfy the Audit Committee Composition Requirement.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | Description | |
| 104 | Cover Page Interactive Data File (embedded within the XBRL document) |
SIGNATURE
Pursuant to the requirements of the Securities ExchangeAct of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HARVARD BIOSCIENCE, INC. | ||
| Date: June 27, 2025 | /s/ Mark Frost | |
| Mark Frost | ||
| Interim Chief Financial Officer and Treasurer | ||
FAQ
Why did Harvard Bioscience (HBIO) receive a Nasdaq deficiency notice?
What is the deadline for HBIO to regain compliance with Nasdaq's audit committee rule?
What action does HBIO plan to take to fix the audit committee shortfall?
Does the 8-K/A include any financial results or earnings information?
Could HBIO be delisted from Nasdaq?
